Prof. Shengping HOU | Medicine and Dentistry | Best Researcher Award
Director of Beijing Institute of Ophthalmology at Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, China
Dr. Shengping Hou is a prominent figure in ophthalmology, currently serving as a Professor and Director at the Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Capital Medical University. With extensive experience in ocular immunology and stem cell biology, he has contributed significantly to advancing research in vision science. His leadership roles and numerous research grants highlight his dedication to developing innovative solutions for ocular diseases. Dr. Hou has delivered invited lectures at international conferences and is actively engaged in professional service, serving as an ad hoc reviewer for esteemed journals. His work has earned him several prestigious awards, including national recognition for his achievements in science and technology.
Professional Profile
Education
Dr. Hou earned his Ph.D. in Ocular Immunology from Sun Yat-sen University, China, in 2009, showcasing his foundation in understanding immune-related ocular diseases. He further honed his expertise as a postdoctoral fellow in Ocular Stem Cell Biology at the University of California, San Francisco, in 2016. This educational background has equipped him with cutting-edge knowledge and skills, enabling him to explore and address complex issues in ophthalmology.
Professional Experience
Dr. Hou began his career as an Associate Professor at Chongqing Medical University (2009–2015), where he played a key role in ophthalmology research at the Chongqing Key Laboratory of Ophthalmology. In 2015, he was promoted to Professor, continuing his impactful work at the same institution until 2023. Currently, Dr. Hou serves as the Director at the Beijing Institute of Ophthalmology, where he leads advanced research initiatives and oversees clinical operations.
Research Interests
Dr. Hou’s research interests focus on ocular immunology, ocular stem cell biology, and the genetic basis of ocular diseases. His work delves into understanding the molecular and genetic mechanisms underlying conditions such as VKH syndrome and Behçet’s disease, with the aim of developing innovative treatments. His commitment to translating basic research into clinical solutions highlights his dedication to improving patient outcomes in ophthalmology.
Research Skills
Dr. Hou possesses advanced expertise in genetic and molecular studies, including gene editing and analysis of copy number variants. His skills also encompass stem cell culture techniques, immunological assays, and bioinformatics tools for studying ocular diseases. Additionally, his experience in securing and leading research grants demonstrates his strategic planning and leadership abilities in scientific endeavors.
Awards and Honors
Dr. Hou has received numerous awards for his contributions to ophthalmology and scientific research. These include the First Prize for the Achievement in Science and Technology from Chongqing (2010, 2015) and the Chinese Health Ministry (2012). In 2018, he was awarded the Second Prize for Scientific and Technological Progress of China, reflecting the national recognition of his impactful work. His accolades underscore his commitment to advancing knowledge in vision science and his leadership in the field.
Conclusion
Dr. Shengping Hou is a highly accomplished researcher with significant contributions to ocular immunology and stem cell biology. His academic leadership, research funding success, and national awards make him a strong candidate for the Best Researcher Award. However, further emphasis on international collaboration, impactful publications, and translational innovations could make his candidature even more competitive. Overall, Dr. Hou’s accomplishments and leadership in ophthalmology research align well with the criteria for this prestigious award.
Publication Top Notes
- Ocular immune-related diseases: molecular mechanisms and therapy”
- Authors: Wang, Y.; Gao, S.; Cao, F.; Lei, F.; Hou, S.
- Year: 2024
- “m6A-methylase METTL3 promotes retinal angiogenesis through modulation of metabolic reprogramming in RPE cells”
- Authors: Zhou, Q.; Liu, X.; Lu, H.; Yang, P.; Hou, S.
- Year: 2024
- “A novel metric of autoimmune disease burden and its estimated incidence across different stages in the life cycle of women”
- Authors: Cao, F.; Pan, H.-F.; Hou, S.
- Year: 2024
- “A feedback loop driven by H3K9 lactylation and HDAC2 in endothelial cells regulates VEGF-induced angiogenesis”
- Authors: Fan, W.; Zeng, S.; Wang, X.; Li, N.; Hou, S.
- Year: 2024
- Citations: 3
- “Transcription factor EGR2 alleviates autoimmune uveitis via activation of GDF15 to modulate the retinal microglial phenotype”
- Authors: Li, W.; He, S.; Tan, J.; Yang, P.; Hou, S.
- Year: 2024
- Citations: 2
- “Icariin alleviates oxygen-induced retinopathy by targeting microglia hexokinase 2”
- Authors: Li, X.; Wang, G.; Li, N.; Zhou, Q.; Hou, S.
- Year: 2024
- Citations: 1
- “Autophagy-mediated activation of the AIM2 inflammasome enhances M1 polarization of microglia and exacerbates retinal neovascularization”
- Authors: Liu, X.; Zhou, Q.; Meng, J.; Mao, L.; Hou, S.
- Year: 2024
- Citations: 1
- “Polyvinylpyrrolidone-curcumin nanoparticles with immune regulatory and metabolism regulatory effects for the treatment of experimental autoimmune uveitis”
- Authors: Cao, F.; Liang, K.; Tang, W.-W.; Tao, L.-M.; Wang, X.
- Year: 2024
- Citations: 6
- “Trends and cross-country inequalities in the global burden of osteoarthritis, 1990–2019: A population-based study”
- Authors: Cao, F.; Xu, Z.; Li, X.-X.; Hou, S.; Pan, H.-F.
- Year: 2024
- Citations: 14
- “YY1 Lactylation Aggravates Autoimmune Uveitis by Enhancing Microglial Functions via Inflammatory Genes”
- Authors: Huang, J.; Wang, X.; Li, N.; Yang, P.; Hou, S.
- Year: 2024
- Citations: 9